<DOC>
	<DOCNO>NCT02376985</DOCNO>
	<brief_summary>To examine whether occurrence oral mucositis reduce dental oral management patient compare use dental oral management instruction dental oral surgeon ( dental oral management group ) observation group ( brush instruction group ) randomize , control study female use everolimus estrogen receptor-positive , hormone therapy-resistant refractory breast cancer .</brief_summary>
	<brief_title>Evaluation Oral Care Prevent Oral Mucositis ER Positive MBC Patients Treated With Everolimus : Phase 3 RCT</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Female patient histological diagnosis breast cancer ( regardless histological subtype breast cancer ) . 2 . Diagnosis metastatic recurrent breast cancer satisfy either . 1 . Distant metastasis present inoperable time first examination ( Stage IV , 3.1 Clinical stage classification ) 2 . Progression distant metastasis recurrence breast cancer treatment ( surgery treatment prior surgery ) 3 . Histologically confirm diagnosis ERpositive breast cancer 4 . Postmenopause 5 . Any condition indicate resistance aromatase inhibitor therapy . The aromatase inhibitor therapy need recent therapy . 1 . Recurrence ongoing adjuvant therapy aromatase inhibitor , recurrence within 12 month adjuvant therapy aromatase inhibitor 2 . Progression ongoing aromatase inhibitor therapy advance breast cancer , progression within 1 month end aromatase inhibitor therapy 6 . No one prior chemotherapy ( antineoplastic drug ) since diagnosis metastatic recurrent breast cancer 7 . Aged ≥20 year 8 . PS 01 . ( ECOG scale ) . 9 . Previous treatment ( include adjuvant therapy ) satisfy condition . 1 . Hormone therapy : At least 7 day elapse last administration hormonal therapy . 2 . Radiotherapy : At least 14 day elapse last irradiation . 10 . Organ function ( within 4 week enrollment ) satisfy condition . 1 . Neutrophil count ( band cell + segment cell ) ≥1,500/mm3 , white blood cell count ≥3,000/mm3 2 . Platelet count ≥100,000/mm3 3 . Total bilirubin ≤2.5 × ULN 4 . AST ( GOT ) ALT ( GPT ) ≤2.5 × ULN 5 . Serum creatinine ≤1.5 × ULN 11 . Cardiac function satisfies either . 1 . No cardiac disorder : No fatigue , palpitation , shortness breath , anginal pain everyday activity confirm interview . 2 . Has cardiac disorder limit movement , patient confirm experience fatigue , palpitation , shortness breath , anginal pain everyday activity , health status deem maintained treatment . 12 . Informed consent obtainable subject document form use Consent Form . 1 . Edentulous jaw ( upper low jaw ) 2 . Occurrence oral mucositis within 1 month prior randomization 3 . Chemotherapy use within 1 month prior randomization 4 . Exemestane monotherapy ( exclusion criterion meet ≥3 month elapse since last exemestane treatment ) recent therapy 5 . Previous mTOR inhibitor treatment ( everolimus , etc . ) 6 . Interstitial pneumonia pulmonary fibrosis . 7 . Received drug treatment know strong inhibitory inductive effect cytochrome P450 ( CYP ) 3A isozymes ( rifabutin , rifampicin , clarithromycin , ketoconazole , itraconazole , voriconazole , ritonavir , telithromycin ) ( See Table 4.1.2.1 4.1.2.2 list prohibit concomitant drug ) . 8 . Positive result HBs antigen , HBc antibody and/or HBs antibody . 9 . HCV infection history HCV infection . 10 . History hypersensitivity protocol treatment drug vehicle drug preparation . 11 . Multiple active cancer ( homochronous multiple cancer , heterochronous multiple cancer cancerfree period le 5 year prior randomization ) . Carcinoma situ deem cured local treatment ( lesion intraepithelial carcinoma mucosal cancer ) include active multiple cancer . 12 . Overexpression HER2 ( Her2/neu , Erb B2 ) , condition consider indicated trastuzumab ( herceptin® ) treatment ( state HER2 expression unknown , patient exclude , treat eligible ) . In word , patient satisfy condition exclude . At either primary metastatic lesion : 1 . Strongly positive , `` 3+ '' HER2 IHC . 2 . Positive `` + '' FISH 13 . Brain metastasis require treatment intracranial hypertension emergency irradiation brain . 14 . Extensive liver metastasis , lymphangitic lung metastasis accompany dyspnea . 15 . Pleural effusion , ascites , pericardial effusion require emergency treatment . 16 . Concurrent active infectious disease . 17 . With uncontrolled diabetes mellitus currently receive insulin therapy . 18 . Difficulty participate study due mental illness psychiatric symptom . 19 . With another reason recognize inadequate participate study doctor .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>